Biostar Pharmaceuticals, Inc. Announces Its Full Year and Fourth Quarter 2014 Financial Results

Full Year 2014 Financial Highlights
- Net sales increased by $8.7 million, or 16.5%, year over year, from $52.7 million in 2013 to $61.4 million in 2014.
- Gross profit grew by approximately 17.9% from $25.7 million in 2013 to $30.3 million in 2014.
- Cash and cash equivalents was $1.7 million at December 31, 2014, an improvement as compared to December 31, 2013;
- Net income was $4.8 million; basic and diluted earnings per share was $0.33.
Fourth Quarter 2014 Financial Highlights
- Net sales in the fourth quarter of 2014 was $14.4 million as compared to $11.0 million during the same period in 2013, representing a $3.4 million, or 31.0% increase.
- Gross profit increased by $1.6 million during the quarter.
- Net income for the quarter was $2.7 million.

XIANYANG, China, April 15, 2015 -- Biostar Pharmaceuticals Inc. ( BSPM ) ("Biostar", "we" or the "Company"), a manufacturer and marketer of pharmaceutical and health supplements to treat a variety of diseases and ailments, headquartered in China, today announced its results of operations for the full year and the quarter ended December 31, 2014.

Published: 16 April 2015
Written by Editor
Nasdaq   Financial Results   Up on News  
Read more: Biostar Pharmaceuticals Inc ( BSPM )

Horizon Pharma plc to Acquire Hyperion Therapeutics, Inc. for $46.00 per Share or $1.1 Billion in Cash

Addition of RAVICTI(R) (Glycerol Phenylbutyrate) Oral Liquid and BUPHENYL(R) (Sodium Phenylbutyrate) Tablets and Powder Significantly Expands Horizon's Orphan Business; Transaction Is Expected to Be Immediately Accretive to Adjusted Earnings Per Share and Contribute Approximately $100 Million in Adjusted EBITDA in 2016; Conference Call Today at 8 A.M. ET to Discuss Transaction

DUBLIN, IRELAND and BRISBANE, CA--(Marketwired - Mar 30, 2015) - Horizon Pharma plc (NASDAQ: HZNP) and Hyperion Therapeutics, Inc. (NASDAQ: HPTX) today announced they have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Hyperion's common stock for $46.00 per share in cash or approximately $1.1 billion on a fully diluted basis. The per share consideration represents a premium of approximately 35 percent to Hyperion's volume weighted average price for the trailing 60-days. The proposed transaction has been unanimously approved by both companies' boards of directors.

Published: 30 March 2015
Written by Editor
Nasdaq   M & A   Up on News  
Read more: Horizon Pharma plc ( HZNP )

Teva Reinforces Leadership Position in CNS with Acquisition of Auspex

Expected to strengthen Teva's core CNS franchise, establish Teva’s leadership in underserved movement disorders space, provide compelling new treatment options for patients in need, and enhance Teva’s long-term revenue and earnings growth

All-Cash Transaction with Enterprise Value of $3.2 Billion

JERUSALEM & LA JOLLA, Calif.-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), today announced that they have entered into a definitive merger agreement under which Teva will commence a tender offer for all of the outstanding shares of Auspex at $101.00 per share in cash, representing total consideration of approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value. This transaction is expected to enhance Teva’s revenue and earnings growth profile and strengthen its core central nervous system (CNS) franchise with the addition of Auspex’s portfolio of innovative medicines for people who live with movement disorders. The transaction has been unanimously approved by the Boards of Directors of both Teva and Auspex, and key shareholders of Auspex have entered into agreements indicating their support for the transaction.

Published: 30 March 2015
Written by Editor
Nasdaq   M & A   Up on News  
Read more: Auspex Pharmaceuticals Inc ( ASPX )

New In Vitro Study Presented at the American College of Cardiology Meeting Suggests Omega-3 Fatty Acid EPA Pre-Treatment Reduces Oxidative Damage and May Provide Atheroprotective Benefit Versus Other Triglyceride Lowering Agents

Study Shows Unique Protection of Small Dense LDL From Oxidative Damage That Results in Endothelial Cell Benefits

BEDMINSTER, NJ and DUBLIN, IRELAND--( March 16, 2015) - Amarin Corporation Plc (AMRN) announced today the presentation of findings from a new in vitro study showing that pretreatment with eicosapentaenoic acid (EPA), an omega-3 fatty acid, reduced oxidation of small dense LDL (sdLDL) and resulted in improved endothelial function when compared to other triglyceride (TG)-lowering agents, including fenofibrates, niacin and gemfibrozil. The research was presented today at a peer-reviewed poster session at the American College of Cardiology Scientific Session in San Diego, California.

Published: 18 March 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Amarin Corporation Plc ( AMRN )

SciClone Reports 2014 Financial Results and 2015 Outlook

Board of Directors Approves Additional $15 Million for Share Repurchase in 2015

FOSTER CITY, CA--(Mar 11, 2015) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the fourth quarter and year ended December 31, 2014.

  1. Endo International plc ( ENL )
  2. Pharmacyclics Inc ( PCYC )
  3. BioSyent Inc ( RX )
  4. Valeant Pharmaceuticals International Inc ( VRX )
  5. Eagle Pharmaceuticals Inc ( EGRX )